Aurgalys Team
Selected Customers
Home
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]
 

June 4th, 2015: Aurgalys releases an analyst report on Diaxonhit [Alternext:ALEHT]

juin 04, 2015

Paris-Evry, France, June 4th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, issued an analyst report on Diaxonhit

« Diaxonhit reported positive results from the CARGO II clinical study for Allomap, a blood test used for heart transplant rejection monitoring. The study, conducted on European patients, demonstrated similar results obtained in the previous CARGO I study, performed in the US. Last April, during a symposium organized by CareDx and Diaxonhit, interesting data were presented regarding new opportunities for extended use of the Allomap test: a correlation between the Allomap score and patient long-term survival could validate its use as a prognosis test; Allomap combination with a donor-derived cell-free DNA test could improve its performance. Diaxonhit also recently announced the licensing of therapeutic assets to Felicitex Therapeutics that could represent significant upside through upfront and milestones payments, as well as royalties on sales, should the products reach the market. We maintain our valuation of Diaxonhit at €105.2M (Enterprise value). This represents a value of €1.64 per share including estimated net cash of €10.6M. »

You can download analyst report (in English) on the following link:

Comments are closed.